In Vivo is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beckman Coulter Genomics

Division of Danaher Corp.
www.agencourt.com

Latest From Beckman Coulter Genomics

LaserGen Inc.

LaserGen is developing a proprietary set of designer nucleotides, synthetic versions of the building blocks of DNA, which can be more easily manipulated to enhance the speed and readout quality of high-throughput sequencing.
Strategy Business Strategies

NABsys Inc.

It currently costs about $10 million to sequence the whole human genome. Reducing the cost to $100,000 will enable experimentation that can elucidate genetic contributions to major diseases. By cutting the cost to $1,000 or less, NABsys Inc. hopes to make genome sequencing an integral part of every individual's routine medical care.
BioPharmaceutical

Deal Statistics Quarterly, Q2 2005

In this issue, we present another installment of our quarterly review of dealmaking-for April-June 2005. Our data comes from Windhover's Strategic Intelligence Systems, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
BioPharmaceutical Medical Device

Instrumental Improvement: Solexa Merges With Lynx

Reverse merging into Lynx gives high-throughput sequencing play Solexa the instrument development capabilities, Nasdaq listing and US presence it lacked. What's more, combining Solexa's sequencing technology with the commercial infrastructure at Lynx was enough to secure top-notch management and cash to see the company through to its first product offering, expected as early as late 2005.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
  • Services
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Agencourt Bioscience Corp.
  • Cogenics
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Danaher Corp.
  • Senior Management
  • R. Brian McKernan, Pres. & CEO
    Lynn Doucette-Stamm, PhD, VP, Bus. Dev.
  • Contact Info
  • Beckman Coulter Genomics
    Phone: (978) 867-2600
    500 Cummings Ctr.,
    Ste. 2450
    Beverly, MA 01915
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register